## **CURRICULUM VITAE**

## BIBI FARIDHA BINTI MOHD SALLEH B.Pharm (USM), M.Pharm (Clinical Pharmacy) (UKM), RPh.

#### **PERSONAL DETAILS**

Name : Bibi Faridha binti Mohd Salleh

Gender : Female

Date of Birth : 2<sup>nd</sup> September 1981

Nationality : Malaysian

Marital Status : Married

Current Address : No.3, Jalan P11H/8, Precinct 11, Putrajaya

Working Address : Pharmacy Policy and Strategic Planning Division

Ministry of Health Malaysia Lot 36, Jalan Universiti,

46200 Petaling Jaya, Selangor

E-mail : <u>bibifaridha@gmail.com</u> / <u>bibifaridha@moh.gov.my</u>

Telephone(s) : +603-7841 3352 (work) / +6016-888 4190 (mobile)

Fax No. : +603-7986 2222

#### **ACADEMIC QUALIFICATION**

2011 – 2012 Master of Clinical Pharmacy (M.Pharm), Universiti Kebangsaan Malaysia

2000 – 2004 Bachelor of Pharmacy (B.Pharm), Universiti Sains Malaysia

1999 – 2000 Matriculation, Universiti Sains Malaysia

#### PROFESSIONAL MEMBERSHIP

Pharmacy Board of Malaysia, Registered Pharmacist, RPh 4824

#### **POSITION HELD & WORK EXPERIENCE**

		Position Held & Work Experience
1.	Dates	Nov 2013 - current
	Position Held	Pharmacist UF48 – UF54
		Sectional Head
		National Medicines Policy Section
		Pharmacy Policy and Strategic Planning Division
		Ministry of Health Malaysia

#### **Position Held & Work Experience**

## Main activities & responsibilities

#### **National Medicines Policy**

- Monitoring and evaluating the plan of action of National Medicines Policy.
- Updating the National Medicines Policy document in timely basis.
- Involvement in the activities planned under the Components of National Medicines Policy:
  - o Pharmaceutical Pricing Policy initiatives
    - Strategic Communication Working Group
  - Patient Access Scheme initiatives
    - Involve in the development of the guideline under this initiatives.
  - Orphan Drug and Rare Disease Policy initiatives
    - Ahli Jawatankuasa Penyakit Jarang Jumpa Kebangsaan
    - Ahli Jawatankuasa Pengurusan Produk Orphan, KKM
  - Halal Pharmaceutical initiatives
    - Technical Working Group for the revision of MS2424:2019 – Halal Pharmaceutical

#### Pharmaceutical Services Programme Strategic Plan

- Strategic Management Planning and coordinating the development of the Pharmaceutical Services Programme's Strategic Plan
  - Monitoring and evaluating the progress of the initiatives / activities planned within the specified implementation period.

## Plan of Action for Pharmacy Policy & Strategic Planning Division

- Strategic Management Planning and coordinating the development of the Plan of Action for Pharmacy Policy & Strategic Planning Division
  - Monitoring and evaluating the progress of the initiatives / activities planned within the specified implementation period.

# <u>Health Policy Related Initiatives (Rancangan Malaysia, SDG/UHC)</u>

- Pharmaceutical Services Programme's Liaison officer for Sustainable Development Goal (SDG) / Universal Health Coverage.
- Planning and managing inputs/feedbacks for Rancangan Malaysia for Pharmaceutical Services Programme
- Secretariat for Focus Group (FG) Public Private Partnership (Pharmaceutical Services Programme as Lead Agency)
  - Under Technical Working Group (TWG) Private Healthcare;
     Inter-Agency Planning Group (IAPG) on Services.

		Position Held & Work Experience		
		Research (Current Involvement)		
		<ul> <li>Involvement as part of research team related to SDG 3.b.3 Indicator – Assessing availability and affordability of essential medicines on a sustainable basis.</li> <li>Involvement as part of research team in the ASEAN Health Cluster 3 initiatives (Malaysia as lead country) – To develop ASEAN Framework for Drug Security and Self Reliance focussing on the pooled procurement of Orphan Drugs, Vaccine &amp; Noncommercially viable products (Lead by Pharmaceutical Services Programme, MOH)</li> <li>Involvement as part of research team in the ASEAN Health Cluster 3 initiatives (Malaysia as lead country) – To develop ASEAN Recommendation for Quality Healthcare in Primary Care (Lead by Institute of Health System Research, MOH)</li> </ul>		
2.	Dates	Sept 2012 – Nov 2013		
	Position Held	Pharmacist UF48 Pharmacist in Charge, Ward Pharmacy (Satellite 3) Sarawak General Hospital		
	Main activities & responsibilities	<ul> <li>Setting up new Satellite Pharmacy Unit (fully unit dose system) to cater services for Medical and Geriatric Ward.</li> </ul>		
		Managing Inpatient Pharmacy (Satellite Pharmacy 3).		
		Pharmaceutical care services – Bedside counselling and patient anticoagulation management		
3.	Dates	Jan 2011 – Sept 2011		
	Position Held	Pharmacist UF44 Pharmacist in Charge of Outpatient Pharmacy Department & Medication Therapy Adherence Clinic (MTAC) (Warfarin) Sarawak General Hospital Heart Centre, Kota Samarahan, Sarawak		
	Main activities & responsibilities	Setting up the new Outpatient Unit and Medication Therapy Adherence Clinic (Warfarin)		
		Managing Outpatient Pharmacy Department		
		Actively involved in the Warfarin Clinic (cardiac setting) – patient anticoagulation management (MTAC Warfarin)		
		Actively involved in Phase 2 and Phase 3 Clinical Trials in the Cardiac Unit setting.		
4.	Dates	April 2007 – December 2010		
	Position Held	Pharmacist UF44 Pharmacist in Charge of Medication Therapy Adherence Clinic Unit (Warfarin), Sarawak General Hospital		

		Position Held & Work Experience		
Main activities & responsibilities		Setting up new pharmacy services –Anticoagulant Management Clinic (MTAC Warfarin) in Cardiac & Medical setting		
		Certified Trainer for MTAC Warfarin (Sarawak General Hospital as Centre of Excellence for MTAC Warfarin Training)		
	Outpatient Pharmacy Management			
	Involvement in research:			
	<ul> <li>Phase 2 and Phase 3 Clinical Trials on new anticoagulant in the Cardiac Unit setting.</li> </ul>			
		Anticoagulant therapy management.		
		Quality Use of Medicine activities & campaign as a master trainer.		
		Preceptor for Provisional Registered Pharmacist (PRP).		
5.	Dates	August 2005 – March 2007		
	Position Held	Pharmacist UF41 Pharmacist in Charge of Outpatient Pharmacy, Specialist Clinic, Sarawak General Hospital		
	Main activities &	Outpatient Pharmacy Management		
	responsibilities	Patient education		
		Preceptor for Provisional Registered Pharmacist (PRP).		

#### PERSONAL SKILLS & COMPETENCES

#### • LANGUAGE SKILLS

Mother tongue (s): Malay Language

Other language (s): English

Self-assessment : Understanding Speaking Writing

Malay

10 10 10

Language English 9 8 8

#### SOCIAL SKILLS

Good communication skills, very responsible person and flexible

### COMPUTER SKILLS

Well verse in using Microsoft Office - Excel, Word and Power Point

#### OTHER SKILLS & COMPETENCES

#### **Technical Related Skills**

Certified in Good Clinical Practice (GCP) (2008)

#### Other Skills

PSMB Certified Trainer (TTT: 20153) (2018)

Certified Dining Skill Consultant (2018)

Certified Professional Image Consultant (2017)

#### **RECOGNITION AND AWARD**

- Service Excellence Award (2018)
   Service Excellence Award (2013)
   Pharmaceutical Services Programme, MOH
   Sarawak State Health Department, MOH

#### PAST CONTRIBUTION AND EXPERIENCE

#### A) RESEARCH & PUBLICATIONS

#### **FULL PAPERS**

No.	Research Title		Year
1.	Edwards F, Arkell P, Fong AY, Roberts LM, Gendy D, Wong CS, Ngu JC, Tiong LL, <b>Bibi FMS</b> , Lai LY, Ong TK, Abouyannis M. Bleeding events and associated factors in a cohort of adult patients taking Warfarin in Sarawak, Malaysia <i>J Thromb Thrombolysis</i> <b>2014</b> ;38(2):226-34. (Published online 15 November 2013)	Research Team	2014

#### **JOURNAL SUPPLEMENTS**

No.	Research Title		Year
1.	Anchah L, Izham M, Sim KH, Alan FYY, Yanti NSS, Tiong LL, <b>Bibi FMS</b> , Azmi AH, Yahya H. (2010) The economic and humanistic outcomes of post-acute coronary syndrome in cardiac rehabilitation program: A quasi-experimental design of 12-month follow up. <i>Medical Journal of Malaysia</i> ; Abstracts of National Heart Association of Malaysia 2010: 65 (3)	Research Team	2010

#### **TECHNICAL REPORT**

No.	Research Title		Year
1.	Availability of Essential Medicines in Remote Public Health Facilities Malaysia.	Principal Investigator	2018
	Pharmacy Research Report. Volume 1 2018.	& Writer	
	Izzati Mohd Farok, <b>Bibi FMS</b> , Lau LW, Ramli Zainal.		
2.	Technical Report on 70 <sup>th</sup> World Health Assembly & Other Related Meetings. 2017	Writer & Contributor	2017
	Dr. Helmi Zakariah, Dr. Jamiatul Aida Md Sani, <b>Bibi Faridha Mohd Salleh</b>		

#### **CONFERENCE PROCEEDINGS**

No.	Research Title		Year
1.	C. Wong, A. Fong, P. Arkell, M. Abouyannis, Tiong LL, <b>Bibi FMS</b> , Azura A, Lai YH, Sim KH. A Prospective Cohort Study to Validate Bleeding Risk Scores for Patients on Warfarin in Malaysia: Preliminary Data.	Co- investigator	2011
	Asia Pacific Cardiology Conference 2011.		

<ol> <li>Lawrence Anchah, Sim Kui Hian, Mohd Izham Mohd Ibrahim, Alan Fong Yean Yip, Yanti Nasyuhana Sani, Tiong Lee Len, Bibi Faridha Mohd Salleh, Mohd Azmi Ahmad Hassali, Yahaya Hassan, Karen Tang Siew Lang, Hii Ai Ching, Sii Lik Ngoh. Long-Term Management and Clinical Outcomes of Post-Acute Coronary Syndrome Patient After Modified Cardiac Rehabilitation Program.</li> <li>18<sup>th</sup> Asian Pacific Congress of Cardiology 2011. Abstract P53.</li> <li>Anchah L., Izham M, Sim KH, Alan FYY, Yanti NSS, Tiong LL, Bibi FMS, Hassali MA, Yahaya H. Cost-utility analysis of the modified cardiac rehabilitation program: A preference-based on SF-6D.</li> <li>Malaysian Pharmaceutical Society – Pharmacy Scientific Conference, Abstract No. 104.</li> <li>Anchah L, Sim KH, Izham M, Alan FYY, Sani YN, Tiong LL, Salleh BF, Hassali MA, Hassan Y. Tang KSL, Hii AC, Sii LN. The Effect of Clinical Pharmacy Based Phase I Cardiac Rehabilitation on Quality of Life</li> </ol>	2011
<ol> <li>Anchah L., Izham M, Sim KH, Alan FYY, Yanti NSS, Tiong LL, Bibi Research FMS, Hassali MA, Yahaya H. Cost-utility analysis of the modified cardiac rehabilitation program: A preference-based on SF-6D.</li> <li>Malaysian Pharmaceutical Society – Pharmacy Scientific Conference, Abstract No. 104.</li> <li>Anchah L, Sim KH, Izham M, Alan FYY, Sani YN, Tiong LL, Salleh BF, Hassali MA, Hassan Y. Tang KSL, Hii AC, Sii LN. The Effect of Clinical Team</li> </ol>	2011
FMS, Hassali MA, Yahaya H. Cost-utility analysis of the modified cardiac rehabilitation program: A preference-based on SF-6D.  Malaysian Pharmaceutical Society – Pharmacy Scientific Conference, Abstract No. 104.  4. Anchah L, Sim KH, Izham M, Alan FYY, Sani YN, Tiong LL, Salleh BF, Hassali MA, Hassan Y. Tang KSL, Hii AC, Sii LN. The Effect of Clinical Team	2011
4. Anchah L, Sim KH, Izham M, Alan FYY, Sani YN, Tiong LL, <b>Salleh BF</b> , Research Hassali MA, Hassan Y. Tang KSL, Hii AC, Sii LN. The Effect of Clinical Team	
Hassali MA, Hassan Y. Tang KSL, Hii AC, Sii LN. The Effect of Clinical Team	
Recovery in Patients with Post-Acute Coronary Syndrome.	2010
The 10 <sup>th</sup> Asian Conference on Clinical Pharmacy 2010. ACCP10- 305	
5. <b>Yew KL</b> , Alan Fong YY, Ang CK, Nor Hanim, Chua SK, Chang BC, Tan Co-JN, Annuar R, <b>Bibi FMS</b> , Liew HB, Ong TK, Sim KH. Assessing a investigator Cardiac INR Clinic Performance with Outcome Measures & Adverse Events.	2009
National Heart Association Malaysia (NHAM) Annual Scientific Meeting 2009.	
<ol> <li>Anchah L, Bibi FMS, Lisa J, Fazilawati J, Sim KH, Chan HK, Abu Bakar Co-AM. Adherence Level Among Cardiac Patients by Using Self-Reported investigator Morisky Score at Sarawak General Hospital: A Single Centre &amp; writer Experience.</li> </ol>	2009
National Heart Association Malaysia (NHAM) Annual Scientific Meeting 2009.	
7. <b>FMS Bibi</b> , L.L Tiong, K.T Yong, H. Mahali, H.M Sapuan, N. Mateni, Principal A.Y.Y Fong, C.C Tan, K.H Sim. A Three Months Pharmacy experience in Warfarin Clinic of Cardiac Setting, Sarawak General Hospital. & writer	2008
National Pharmacy R&D Conference 2008.	
8. Anchah L, Sim KH, Izham M, Alan FYY, Yanti NS, Tiong LL, <b>Bibi FMS</b> , Azmi AH. The Prescribing Pattern for Secondary Prevention ACS with or without Asymptomatic Left Ventricular Systolic Dysfunction. Insight from CRP Study: A Single Centre Experience.	2008
National Pharmacy R&D Conference 2008.	
9. Anchah L, Izham M, Sim KH, Alan FYY, Yanti NS, Tiong LL, <b>Bibi FMS</b> , Research Azmi AH, Yahaya H. The EuroQoL EQ-5D and short-form 36 (SF-36) Health Survey Questionnaires: Reliability in ACS Patient Based Studies. (2008)	2008
- 10-0-10-10	
MPS Scientific Meeting 2008, OPP13.	
	2008

No.	Research Title		Year
11.	Fong AYY, <b>Bibi FMS</b> , Lai LYH, Ang CK, Liew HB, Chin WM, Liew CK, Ong TK, Annuar R, Joshi P, Sim KH. The feasibility of a Portable Prothrombin Time Device (Coaguchek) in the management of patients with Mechanical Prosthetic Heart Valves. (2007).	Co- investigator & writer	2007
	<b>Asian Cardiology Conference 2007:</b> 2 <sup>nd</sup> Runner Up Prize Oral Presentation.		

### B) INVOLVEMENT IN CLINICAL TRIAL RESEARCH

No.	Clinical Research Title		Year
1.	Phase 3 Clinical Trial – EFC6204 TAO Study	Site	2011
	A Multicentre, Randomized, triple-dummy trial to compare the efficacy of Otamixaban with Unfractionated Heparin + eptifibatide, in patients with Unstable angina/ Non-ST segment Elevation Myocardial Infarction scheduled to undergo an early invasive strategy.	Pharmacist	
2.	Phase 2 Clinical Trial – Sanofi SEPIA ACS1 TIMI 42	Site	2011
	A Multicentre, Randomized, Active-Controlled Phase 2 Trial of Otamixaban, a Direct Xa Inhibitor in Patients With Non-ST Elevation Acute Coronary Syndrome	Pharmacist	

## C) FORMAL COURSES / ATTACHMENT

No.	Attachment / Course Title	Year
1.	Improving Access to Medicines through Strategic Public Procurement Practice	2019
	WHO Country Office for Malaysia, Brunei Darussalam & Singapore & Ministry of Health Malaysia. (1 week)	
	29 – 31 January 2019	
2.	Pharmaceutical Policy Analysis Course	2018
	WHO Collaborating Centre for Pharmaceutical Policy, Universiteit Utrecht, Utrecht, Netherland (5 days)	
	10 – 14 July 2018	
3.	Attachment at Essential Medicines and Health Products (EMP) Department, World Health Organization (WHO)	2017
	WHO Headquarter & United Nation, Geneva, Switzerland (3 days)	
	18 – 20 May 2017	
4.	Malaysia Representative (Technical Officer) to the 70 <sup>th</sup> Session of World Health Assembly (WHA70)	2017
	United Nation, Geneva, Switzerland (1 week)	
	22 – 31 May 2017	
5.	Pharmaceutical Pricing and Reimbursement Policies	2014
	WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies & Main Association of Austrian Social Security Insurance (HBV), Vienna, Austria (10 days)	
	3 – 10 November 2014	

No.	Attachment / Course Title	Year
6.	Medication Therapy Adherence Clinic Attachment (Warfarin) – 1 <sup>st</sup> Cohort (Latihan Dalam Perkhidmatan Dalam Negara)	2007
	Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan (3 weeks)	

### D) INVOLVEMENT IN PUBLICATIONS

No.	Title	Year
1.	Malaysian Guideline for the Management of Orphan Drugs	Drafting
	Editorial committee and contributor	(expected 2020)
2.	Garis Panduan Pengendalian Ubat Sampel di Fasiliti Kementerian Kesihatan Malaysia	Drafting
	Contributor	(expected 2020)
3.	Guideline on the Management of Medicines Donation	Drafting
	Editorial Committee and contributor	(expected 2020)
4.	MS2424:2019 – Halal Pharmaceuticals – General Requirements (First Revision)	2019
	<ul> <li>Members of working Group on revision of MS2424</li> </ul>	
5.	Panduan Penggunaan Ubat-ubatan dari Perspektif Islam	2018
	<ul> <li>Editorial Committee and contributor</li> </ul>	
6.	Guideline on Proposal Submission for Patient Access Scheme (PASc) Implementation in Ministry of Health	2018
	<ul><li>Contributor</li></ul>	
7.	Pharmaceutical Services Programme Strategic Plan 2017-2020	2017
	<ul> <li>Project Secretariat and Writer</li> </ul>	
8.	Annual Report Pharmaceutical Services Programme	2015-2019
	<ul> <li>Editorial Committee and Contributor</li> </ul>	
9.	Master Plan of Action – Malaysian National Medicines Policy, 2 <sup>nd</sup> Edition	2014
	Editorial Committee	

## E) INVOLVEMENT IN TECHNICAL WORKING GROUP / POLICY DIALOGUE

No.	Title	Year
1.	Technical Working Group For The Revision Of MS2424:2012 – Halal Pharmaceuticals - General Guidelines	2018-2019
	Jabatan Standards Malaysia (Cyberjaya, Selangor)	

No.	Title	Year
2.	Round Table Discussion on the Development of 'Dasar Halal Negara' – (Government Cluster)	2018
	Jabatan Kemajuan Islam Malaysia (JAKIM) Mac 2018	
3.	Technical Working Group – Midterm Review RMK11 – Mencapai Akses Sejagat kepada Penjagaan Kesihatan Berkualiti	2017
	Bahagian Perancangan, KKM 26 – 27 Oct 2017	
4.	Technical Working Group – Enhancing Malaysia's Export Performance Lab - Pharmaceutical Generic Industries.	2017
	Ministry of Finance in collaboration with PEMANDU Associates 14 – 25 August 2017 (Putrajaya)	
5.	APEC Policy Dialogue on Rare Disease – Development of APEC Rare Disease Action Plan	2017
	APEC LSIF Rare Disease Network 6 – 7 June 2017 (Beijing, China)	